Compare Kyndryl Holdings Inc (KD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Sana Biotechnology Inc — how do they compare? Kyndryl Holdings Inc trades at $12.95 (market cap $2.91B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: Kyndryl Holdings Inc is far larger — about 2.6× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| KD | SANA | |
|---|---|---|
Market Cap | $2.91B | $1.13B |
Sector | Technology | Health |
52-Week High | $33.14 | $5.92 |
52-Week Low | $10.59 | $2.68 |
Enterprise Value | $5.74B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $12.87, down 5.58% on the day, with a neutral technical signal and mixed earnings history. The company reported a net income of $252 million in 2025, reversing prior losses, and maintains strong operating cash flow of $942 million. Recent news includes an acquisition to boost AI services and Q1 2027 results showing a revenue miss but an EBITDA beat.
The stock presents a cautious opportunity with a consensus price target of $13.50, offering modest upside. Risks include inconsistent earnings, high debt levels, and ongoing investigations. Analyst sentiment is predominantly hold, reflecting uncertainty amid strategic shifts toward growth areas like AI and cloud partnerships.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
